Security Name: 7.99% Mankind Pharma Limited 16 Apr 2026
ISIN:
INE634S07017
Taxable
Tax Category
16 Apr, 2026
Maturity Date
(9 Mo 22 D to mature)
Half Yearly
Interest Payment Frequency
Yes
NRI Eligibility
16 Oct, 2024
Allotment Date
NA
Put Date
16 Oct, 2025
Next Interest Payment Date
15 days
Shut Period
Both
Active on NSDL/CDSL
Non-Guaranteed
Type of Guarantee
No
Perpetual
Private Placement
Mode of Issue
Listed
Listing Details
Non Public Sector Undertaking
Type of Issuer
Quote Not Available
Dirty Price
7.99%
Coupon
Fixed Interest
Coupon Basis
Quote Not Available
Current Yield
01 Oct, 2025
Record Date
YOUR EARNING
Your Investment
Final Payout
₹0
Error Generating Cashflow 😥. We are looking into this.
*All Interest Payments will be subject to TDS (Not Applicable on Government Securities and Tax Free Bonds)
YOUR RISK
Repayment Priority
Higher the level, higher the priority of investment repayment on default
Security with Collateral?
An investment secured with collateral helps
ISSUER
Mankind Pharma Limited
MPL is involved in developing, manufacturing and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products. It is India’s fourth largest pharmaceutical company in terms of domestic sales and has been ranked number one over the last seven years by the volume of prescriptions. It also ranks third in the domestic market in terms of sales volumes. MPL’s pharmaceuticals portfolio caters to various acute and chronic therapeutic areas including anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/CNS, VMNs, respiratory, etc.
The ratio in FY24 is 0.07x and it was 0.08x in FY23, indicating almost no changes in the debt level of the issuer.
Debt/EBITDA
The ratio in FY24 is 72.56x and it was 38.58x in FY23, indicating significant increase in the debt servicing ability of the issuer due to significant increase in the profitability and reduction in the finance cost of the issuer.
Interest coverage ratio
Recent News
Mankind Pharma gets CDSCO Panel nod for bioequivalence study of Resmetirom Tablets
Apr 21, 2025 | Mankind Pharma Limited
Mankind Pharma gets NCLT nod for amalgamation of Shree Jee Lab, JPR Labs, Jaspack
Apr 23, 2025 | Mankind Pharma Limited
Related Videos
Bonds vs Other Asset Classes
Compare the Bonds against other asset classes like Fixed deposits and Mutual Funds
Taxation
The Complex Terrain of Tax Implications for Fixed-Income Investments!
STEPS TO BUY THIS BOND
Information required for KYC
PAN Card
Bank Account Proof
Aadhaar Card
Demat Account Proof
How to exit the investment?
To know more about the Bond and the issuer, download the Information Memorandum.
To read about the reasons for the ratings assigned to the Bond, download the Rating Rationale.
Clean Price
Yield (YTM)
Principal Amount
Accrued Interest from
Select the number of units below
BOND VALUE DETAILS
Face Value
Market Value
Stamp Duty
Select a Settlement Date:
Total Investment
| Cashflow for INE634S07017 |
|---|
| Disclaimer: The actual dates and interest amounts can vary depending on Bank closures, holidays etc. Tax Deducted at Source (TDS) is applicable on interest receivable based on relevant tax regulations. You can avail TDS credit while filing your Income Tax Return (ITR). |
|---|
| Security Name |
|---|
| 7.99% Mankind Pharma Limited 16 Apr 2026 |
| Credit Rating |
|---|
| AA + /Stable by CRISIL AA + /Stable by ICRA |
| Coupon Frequency |
|---|
| Half Yearly |
| Face Value |
|---|
| ₹1,00,000 |
| Coupon |
|---|
| 7.990000% |
| YTM or YTC |
|---|
| YTM |
| Maturity Date |
|---|
| 16/04/2026 |
| Security |
|---|
| Senior Secured |
| No. of Bonds |
|---|
| 1 |
| Settlement Date |
|---|
| Principal Amount |
|---|
| ₹NaN |
| Accrued Interest |
|---|
| ₹0 |
| Stamp Duty |
|---|
| ₹0 |
| Total Amount Payable |
|---|
| ₹NaN |
| Price |
|---|
| ₹NaN |
| Yield |
|---|
| % |
| Year | Payment Date | Amount | Amount after TDS | Payout Type |
|---|
Quote Not Available for purchase
Disclaimer: Investments in Debt Securities/ Municipal Debt Securities/ Securitised Debt Instruments are subject to risks including delay and/ or default in payment. Read all the Offer Related documents carefully.
Source: Issuer website, Rating Rationale, Issuer Annual Report, Information Memorandum and News from Google.
